Status: Not yet recruiting
The LINFU® U.S. Registry for the in the General Population Without Risk Factors
Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions.. In this study, LINFU® will be evaluated in the general population with no risk factors and who exhibit no signs or symptoms of disease, This study will help determine if LINFU® can be used to help identify early, asymptomatic pancreatic ductal adenocarcinoma (PDAC) or their precursor lesions (PanIn-2, PanIn-3).
Participants needed: 500
Trial details
Age: 18-90Biological sex: AllType: ObservationalSponsor: Adenocyte, LLCUpdated: Jul 31, 2024Duration: 5 Years
Eligibility criteria
Both males and females will be enrolled and must be at least 18 years of age and... [+4]
Patient under the age of 18 and over the age 90 [+13]